RADNOR, Pa. – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Santiago Arroyo, M.D., Ph.D., to its Board of Directors. Dr. Arroyo brings more than 30 years of experience in academic neurology and pharmaceutical...
Latest News
Cells that form cutaneous squamous cell carcinoma tumours prepare themselves to migrate to the lymph nodes to metastasise other organs, and they make changes so that they can survive this process. According to a study led by researchers from the Inflammatory and Neoplastic Dermatological Diseases Research Group at the Hospital del Mar Medical Research Institute, published in the journal Life Science Alliance, these cells stop consuming glucose so that they can survive by using LDL cholesterol molecules, the so-called bad cholesterol. This new marker may be a promising candidate for treatments involving lipid metabolism inhibitors targeting these cells to prevent metastasis.
HOUSTON – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced completion of the six-patient safety lead-in portion of the Company’s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product...
HOUSTON, Texas — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided an update on the progress and clinical observations from the Phase 1 APOLLO study. The Company’s Phase 1 APOLLO...
HOUSTON, Texas — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that data from the Phase 1 APOLLO study will be presented in two posters at the 67th American Society of Hematology (ASH)...
London — MarketsandMarkets is pleased to announce the 4th Annual Orphan Drugs and Rare Diseases Conference, which is set to take place on the 9th-10th of October 2023 in London, UK. After the resounding success of the third annual conference, we are excited to bring together industry experts, researchers, and...
Calgary, Alberta – Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBraiN Inserm Lab in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore...
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the “Company” or “Marvel”), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. The study evaluated MB-204, Marvel’s lead compound (10...
Boston, Mass. – A new study by investigators from Mass General Brigham demonstrated that a remote team focused on identifying, educating and prescribing therapy can improve guideline-directed-medical-therapy (GDMT) adherence in patients with type 2 diabetes and high cardiovascular and/or kidney risk. The research team observed that patients who received education...
Chandan Bariya of Sankariya village of Limkheda Taluka was brought to the clinic of Samir Brahmbhat after complaining of severe abdominal pain. Tests demonstrated that the girl was suffering from a rare disorder called Rapunzel syndrome, where an individual pulls one’s hair out and then eats it. This condition normally...